9 minutes for each presentation and 3 minutes for discussion after each presentation

10:30 am - 10:42 am: Long-term Outcomes of Topical Cyclosporine 0.05% Treatment in Patients with Dry Eye (Daliya Dzhabe, MD)
10:42 am - 10:54 am: Orally Administered Connexin43 Hemichannel Inhibitor of the Inflammasome for the Treatment of Geographic and Diabetic Retinopathy (Brian Levy, OD, MSc)
10:54 am - 11:06 am: Drug Retention Rate of Adalimumab in Uveitis: Real-World Data from the Spanish Biotherapies in Uveitis (BioÚvea) Study Group (Maite Sainz de la Maza, MD, PhD)
11:06 am - 11:18 am: Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study (Quan Dong Nguyen, MD, MSc)
11:18 am - 11:30 am: Composite Endpoint Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients with Noninfectious Uveitis (Muhammad Hassan, MD)
11:30 am - 11:42 am: Collaborative Ocular Tuberculosis Study (COTS) Consensus Guidelines on Initiating Anti-tubercular Therapy in Presumed Tubercular Choroiditis (Sarakshi Mahajan, MD)
11: 42 am - 11: 54 am: Congenital Toxoplasmosis as One Phenocopy of North Carolina Macular Dystrophy (NCMD/MCDR1) (Kent Small, MD)
11:54 am – 12:00 noon: Discussion

Free Paper

Saturday, 4/4/2020